Educational only — not medical advice, not a diagnosis. This page describes what users commonly discuss with their licensed healthcare provider around this topic. We do not diagnose, treat, cure, reverse, or fix any condition. No compound listed is recommended. Work with a licensed clinician for any decision.
Home/Conditions/Metabolic Syndrome
METABOLIC — EDUCATIONAL GUIDE

Metabolic Syndrome

The constellation of cardiovascular + metabolic risk factors — diagnosed clinically, tracked via a specific marker cluster.

What This Is

Metabolic syndrome is a clinical diagnosis made by a licensed provider based on meeting 3 of 5 criteria: elevated waist circumference, elevated triglycerides, low HDL-C, elevated blood pressure, elevated fasting glucose. It roughly triples cardiovascular disease risk and doubles the risk of progressing to type 2 diabetes.

The marker cluster below is what providers typically review when discussing metabolic-syndrome risk. These markers aren't a substitute for a clinical workup — criteria and cutoffs are specific to the diagnosing organization (NCEP ATP III, IDF, etc.), and only a licensed clinician can apply them.

Biomarkers Users Commonly Track

The following lab markers are commonly discussed with a licensed provider in this context. They are not a diagnostic checklist. Only your clinician can interpret what these values mean for your specific situation.

Fasting Glucose70–89 mg/dL is the metabolic-optimization target
One of the 5 criteria. Cutoff (≥100 mg/dL) varies by diagnostic framework.
Triglycerides<100 mg/dL · ideal <80 mg/dL fasting
Criterion: ≥150 mg/dL fasting.
HDL-C50–80 mg/dL — extremely high levels (>90) carry their own concerns
Criterion: <40 mg/dL men / <50 mg/dL women.
Fasting Insulin<10 mIU/L · ideally 2–6 mIU/L for metabolic optimization
Not a formal criterion — but early indicator most clinicians pull.
ApoB<80 mg/dL (general population); <60 mg/dL (existing CVD or high risk)
Superior CV risk marker to LDL-C — the actual atherogenic particle count.
hs-CRP<1.0 mg/L — often <0.5 mg/L in highly optimized individuals
Systemic inflammation marker often elevated alongside.
ALT<25 U/L is a common metabolic-optimization target
Hepatic fat / NAFLD signal — highly correlated with metabolic syndrome.

Compounds Users Research (Ask Your Clinician)

No compound below is a recommended treatment. These are research-stage or investigational compounds that users commonly look up in this context. Any decision about their use is a conversation with a licensed healthcare provider, under their supervision, with full understanding of risks and your personal history.
Semaglutide
GLP-1 with cardiovascular outcomes data — users with metabolic-syndrome features often discuss with their clinician.
Tirzepatide
Dual-agonist with strong metabolic-marker movement in trials.
Retatrutide
Investigational triple-agonist currently in Phase 3 for metabolic indications — not FDA-approved.

Related Reading

Related Conditions

Insulin ResistanceElevated Visceral FatElevated ApoB (Cardiovascular Risk)
Bring the data to your next visit.

MyProtocolStack lets you log the biomarkers on this page across lab draws, chart the trend, and hand a structured report to your clinician. Better conversations start with better data. We do not replace your provider; we help you show up prepared.

Start tracking free →
Compliance notice: This page is informational and educational only. MyProtocolStack does not provide medical advice, diagnosis, or treatment. All references to biomarkers are educational. All references to compounds describe what users research and typically discuss with their clinician — not endorsements or treatment recommendations. Reference ranges vary by laboratory. Symptom interpretation and any protocol decisions require a licensed healthcare provider. If you are experiencing symptoms, consult your clinician.